Search for: "In Re: Mylan Technologies Inc."
Results 21 - 40
of 76
Sorted by Relevance
|
Sort by Date
18 May 2016, 8:19 am
NuVasive, Inc., No. 15-85 (Commil re-hash – mens rea requirement for inducement) 3. [read post]
18 Apr 2016, 9:58 am
NuVasive, Inc., No. 15-85 (Commil re-hash – mens rea requirement for inducement) 3. [read post]
3 May 2016, 1:42 am
NuVasive, Inc., No. 15-85 (Commil re-hash – mens rea requirement for inducement) 3. [read post]
7 May 2010, 11:11 am
See In re Morris, 127 F.3d 1048, 1055 (Fed. [read post]
15 Apr 2010, 9:20 am
Cal. 1996); Summit Technology, Inc. v. [read post]
2 Sep 2010, 10:51 am
Mylan Labs, Inc., 520 F.3d 1358 (Fed. [read post]
18 Feb 2010, 10:34 am
Most notably there’s Mylan Laboratories, Inc. v. [read post]
10 Feb 2010, 4:47 pm
Mylan Pharmaceuticals Inc. [read post]
14 Nov 2016, 9:16 am
Sud-Chemie AG, No. 16-238 (unduly narrow claim construction) Eligibility: Trading Technologies International, Inc. v. [read post]
8 May 2009, 8:00 am
(Property intangible) US: Supreme Court rules 9-0 that CAFC has jurisdiction to review case remanded by district court to state court: Carlsbad Technology Inc v HIF Bio, Inc et al (Managing Intellectual Property) (Patently-O) US: Anticipation by a laundry list of prophetic DNA sequences: In re Gleave (Holman's Biotech IP Blog) US: Reverse payment settlements and biotechnology (Holman's Biotech IP Blog) US: Biogen seeks review and correction of patent… [read post]
18 Jul 2014, 11:55 am
Wyeth, Inc., 85 Cal. [read post]
1 Feb 2016, 10:43 am
Laboratories, Inc., PurduePharmaceuticals L.P., Rhodes Technologies also representedby JENNIFER LORAINE SWIZE; JOHN JOSEPHNORMILE, JR., New York, NY; ROBERT J. [read post]
19 Feb 2016, 11:57 am
Corporation with no in-state assets, employees, or registered agent, cannot be at home.In re Roman Catholic Diocese of Albany, New York, Inc., 745 F.3d 30 (2d Cir. [read post]
9 Sep 2009, 7:14 am
– Dispute between Wyeth and Dexel (The IP Factor) EpiPen (Epinephrine) – US: King Pharmaceuticals, Meridian Medical Technology file patent infringement suit against Teva following Para IV certification (Patent Docs) Seroxat (Paroxetine) – Israel: not even sublime, just ridiculous – Israel PTO decision in Unipharm v SmithKline Beecham (America-Israel Patent Law) Stelara (Ustekinumab, anti-IL-12 antibody) – Centocor seeks review of BPAI… [read post]
7 Nov 2014, 5:52 am
Teva Pharmaceuticals USA, Inc., 819 F. [read post]
10 Jan 2012, 11:58 pm
Mylan Inc., No. 2:09cv1692, 2009 U.S. [read post]
5 Mar 2015, 5:52 am
Mylan Pharmaceutical, Inc., ___ F. [read post]
21 Oct 2009, 6:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) – US: Shire… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with… [read post]
21 Oct 2009, 5:13 am
In re KGK Synergize (non precedential) (Patently-O) US: Myriad sticks to its business model despite legal action brought by PUBPAT and others: Association for Molecular Pathology v USPTO (Patent Docs) US: Amazing race: Win $250,000 for commercialising biomedical research (Patent Baristas) US: BIO survey on technology transfer shows complexity of university-industry relationships (PatentBIOtech) Products Adderall (Dextroamphetamine, Amphetamine) - US: Shire announces settlement with… [read post]
